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Trends in fluoroquinolone resistance in Campylobacter
Emma L. Sproston,1† Helen M. L. Wimalarathna2† and Samuel K. Sheppard1,*
Abstract
Members of the genus Campylobacter remain a leading cause of bacterial gastroenteritis worldwide. Infection is usually self-
limiting but in severe cases may require antibiotic treatment. In a recent statement by the World Health Organization (WHO)
Campylobacter was named as one of the 12 bacteria that pose the greatest threat to human health because they are
resistant to antibiotics. In this mini review we describe recent trends in fluoroquinolone (FQ) (particularly ciprofloxacin)
resistance in strains of members of the genus Campylobacter isolated from livestock and clinical samples from several
countries. Using evidence from phenotyping surveys and putative resistance prediction from DNA sequence data, we discuss
the acquisition and spread of FQ resistance and the role of horizontal gene transfer and describe trends in FQ-resistance in
samples from livestock and clinical cases. This review emphasises that FQ resistance remains common among isolates of
members of the genus Campylobacter from various sources.
DATA SUMMARY
All external data records cited in the text of this review are
listed in the bibliography at the end of the document.
INTRODUCTION
Members of the genus Campylobacter are the leading cause
of bacterial gastroenteritis in many countries [1, 2]. They
are frequently isolated from the gut of warm-blooded ani-
mals (particularly poultry) [1, 2] and the common patho-
genic species Campylobacter jejuni (approximately 90%)
and Campylobacter coli (approximately 10%) [3, 4] cause
infection in humans, most commonly after consumption of
contaminated or under-cooked food, especially poultry.
Campylobacteriosis is usually self-limiting and rarely
requires antibiotic treatment, except in severe or prolonged
cases [2, 5]. The most common drugs used to treat Cam-
pylobacter infections are macrolides (particularly erythro-
mycin) for laboratory-confirmed cases. Members of the
genus Campylobacter are generally susceptible to erythro-
mycin and in Europe gentamicin (an aminoglycoside) is the
antibiotic to which they have the second lowest antimicro-
bial resistance (AMR) rates, after gentamicin [6]. The fluo-
roquinolones (FQ) are broad-spectrum antimicrobials that
are used to treat a multitude of infections including undiag-
nosed cases of diarrhoea, predominantly by using ciproflox-
acin (CIP) [2, 5, 7–10].
Since the late 1980’s there has been an increasing trend in
the proportion of FQ-resistant strains of members of the
genus Campylobacter isolated from both clinical samples
[11–13] and livestock, where FQs (particularly enrofloxa-
cin) are frequently used to treat animals in intensive pro-
duction [5, 7, 9, 12, 14]. In general it appears that resistance
to FQs, and several other antimicrobials (AM’s), is more
common in C. coli compared with C. jejuni (Table 1) [4, 6,
7, 15, 16] but the reason for this is not fully understood.
However, FQ resistance remains common in both species
[17]. The widespread acquisition of FQ resistance is the
result of spontaneous independent mutations and is acceler-
ated by the horizontal transfer of resistance-conferring
DNA among strains of members of the genus Campylobac-
ter [5, 18]. In response to the rising levels of FQ and other
AMR, restrictions on the use of FQs in animal husbandry
have been implemented in the EU (2003 and 2006) and the
USA (2005) [13, 19, 20], and several specific government-
led AMR surveillance and monitoring programs have been
initiated [21]. However, comprehensive data assessing CIP
resistance in members of the genus Campylobacter has only
become available in recent years [6, 15] and FQs are already
of limited use for treating infections with members of the
genus Campylobacter in many countries [5]. The primary
FQ in Campylobacter AMR testing schemes is CIP, probably
due to its common use in the treatment of diarrhoea. In
Europe, CIP is the only FQ listed, and is a mandatory AM
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to be tested under the harmonised methods scheme for the
monitoring of AMR in isolates of members of the genus
Campylobacter from humans [22]. For isolates of members
of the genus Campylobacter obtained from the major food
animals, nalidixic acid (NAL) (a quinolone) is also included
on the mandatory list of AM’s to be tested for resistance
[23]. Many other studies follow this, where other FQ’s are
rarely included in the AMR testing of Campylobacter iso-
lates. However, the resistance to quinolone and fluoroqui-
noline have a strong correlation [9]. For example, a study
has revealed that 69.8% of isolates of C. jejuni from poultry
were resistant to CIP and 65.1% were resistant to NAL [6].
In other studies, isolates of members of the genus Campylo-
bacter had similar proportions that were resistant to CIP
and NAL [16, 24, 25]. This is most likely to be due to a high
level of resistance being conferred by just a single point
mutation within the quinolone-resistance-determining
region (QRDR) and it being the most common and recog-
nised mechanism for FQ resistance in members of the genus
Campylobacter [5, 7, 14]. If an isolate has developed a high
level of resistance to a FQ drug, it is likely to have similar
resistance levels to other FQ’s.
Here we describe the genetic basis of CIP resistance in
members of the genus Campylobacter and the mechanisms
of emergence and spread among strains and species. Draw-
ing on recent publications that describe CIP-resistance in
isolates from a number of different sources and countries,
we assess if resistance in members of the genus Campylobac-
ter is still rising and review the potential for using DNA
sequence-based approaches to predict FQ-resistance in
members of the genus Campylobacter.
Mechanisms of resistance
In Campylobacter, FQs work by inhibiting a large enzyme,
DNA gyrase, that is involved in DNA replication and tran-
scription [5, 14, 26, 27]. It is now commonly recognised that
the most frequent mechanism of CIP resistance in members
of the genus Campylobacter is a single point mutation
C257T in the gyrA gene, within the QRDR. This results in
an amino acid substitution in the Gyrase A subunit at posi-
tion 86, from threonine to isoleucine [5, 14, 28–31] and has
been reported in all CIP-resistant strains of C. jejuni isolated
from clinical samples in an example study [32]. Other muta-
tions within the gryA gene have been associated with
increased resistance to ciprofloxacin but at lower concentra-
tions and frequency [5, 14, 32, 33]. The gyrA mutation
works synergistically with the most common Campylobacter
drug efflux pump CmeABC, where, when expression is ele-
vated, the emergence of FQ-resistant strains is increased [5,
14]. However, in the absence of the gyrA gene mutation,
over-expression of the CmeABC efflux pump does not gen-
erate ciprofloxacin resistance [5, 28, 32, 34, 35]. Other fac-
tors enhance the level of resistance further, such as the
16 bp inverted repeat (IR) in the cmeR–cmeABC intergenic
region. When this mutation occurs in conjunction with the
C257T-gyrA mutation, the proportion of resistant isolates
increases and a higher mean ciprofloxacin minimum
inhibitory concentration (MIC) is achieved. For example, in
culture at a CIP concentration of 64–512 µgml 1, 30%
resistance was observed in C257T-gyrA mutants compared
with 97% among IR-C257T mutants [28]. In addition a
variant of the cmeABC gene that enhances CIP resistance
(RE-cmeABC) has recently been identified and is increasing
in prevalence [34].
Variation in other genes can also indirectly influence the
level of CIP resistance. For example, variations in the
mutant frequency decline gene (mfd) may have a role, since
the inactivation of this gene has been shown to reduce
mutations 100-fold [5, 36]. Unlike the more prolonged and
often stepwise selection process for macrolide resistance [5],
CIP resistance can accumulate rapidly in the population
through mutation in different strains of members of the
genus Campylobacter and selection pressure enriching for
isolates that have a resistance mutations [14, 18, 27, 37].
Acquisition and spread of resistance
Spontaneous mutation is a major mechanism for acquisition
of FQ-resistance. In an environment where resistance con-
fers a selective advantage, clonal reproduction among resis-
tant lineages will lead to local expansion. Consistent with
this, there is evidence that CIP resistance phenotypes are
more common among certain lineages or clonal complexes
(CC) [38]. This lineage association has been observed
among isolates from UK retail poultry [38] and clinical
samples [39], and several studies have associated ciprofloxa-
cin resistance with certain lineages of members of the genus
Campylobacter, including CC-21, CC-206, CC-353 and CC-
354 [40–45]. However, in contrasting studies in China there
was no association between CC and CIP-resistance pheno-
types, indicating that the acquisition of resistance had
occurred in numerous distantly related strains of members
of the genus Campylobacter [28, 46]. This indicates wide-
spread dispersed resistance rather than clonal expansion of
resistant strains. One explanation for this is the spread of
resistance between strains by horizontal gene transfer
(HGT) [5, 18].
IMPACT STATEMENT
Fluoroquinolones (FQ), especially ciprofloxacin (CIP), are
among the most common treatments for human and ani-
mal infection with Campylobacter – a common cause of
gastroenteritis worldwide. Over time, this has resulted
increased antimicrobial resistance (AMR), making these
drugs much less effective. Here we review current litera-
ture to describe: (i) the mechanisms of FQ resistance in
members of the genus Campylobacter; (ii) acquisition and
spread; (iii) predicting resistance from whole-genome
data; (iv) CIP resistance among clinical isolates; (v) CIP
resistance in livestock; (vi) the potential for spread of
resistance from animals to humans.
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Table 1. Ciprofloxacin (CIP) resistance in members of the genus Campylobacter from clinical, poultry and livestock samples
Sample Country Area Source Sample type Isolates year(s) Species* Resistance to CIP [% (n)] Ref.
Clinical Canada Montreal Human 2002 Cj 41.6 (440) [17]
2013 Cc 50.0 (38)
Canada Ontario Human 2011 Cj 30.8 (180) [53]
2013 Cc 41.0 (39)
USA Selected states Human 2011 Cj 25.8 (5048) [54]
2015 Cc 36.3 (576)
USA USA Human 2011–12 C. Spp. 25.3 (1962) [55]
Peru Lima Human Infant faeces 2008–11 Cj 87.0 (69) [57]
Cc 91.3 (46)
Europe 13 countries Human 2014 Cj 60.2 (11 585) [6]
Cc 68.9 (1500)
Europe 17 countries Human 2015 Cj 60.8 (13 696) [15]
16 countries Cc 70.6 (1754)
France Human 2014 Cj 55.6 (1997) [56]
2015 Cc 64.4 (419)
Poland Bydgoszcz Human Child faeces 2011–13 Cj 65.2 (92) [63]
Cc 71.4 (7)
UK Oxfordshire Human 2008 C.spp. 37.5 (803) [39, 58]
China Beijing Human 1994/2010 Cj 86.7 (203) [25]
Broilers Africa Kenya Chicken Faeces/cloaca Cj 71.0 (31) [24]
Cc 75.0 (4)
China Multiple Chicken Caecae 2008–09 Cj 99.4 (971) [46]
Multiple 2012–14 Cc 99.2 (1021)
China Central Chicken Faeces/cloaca 2012–16 Cj 100.0 (166) [61]
CC 100.0 (40)
Europe 25 countries Chicken Caecae 2014 Cj 69.8 (3317) [6]
8 countries Cc 74.3 (767)
Italy Chicken Cloaca/carcass 2014 Cj 39.0 (99) [62]
2015 Cc 69.7 (41)
Poultry meat China Central Chicken Frozen/fresh 2014 Cj 100.0 (40) [64]
2015 Cc 100.0 (12)
Europe 3 countries Chicken Various 2014 Cj 65.6 (308) [6]
Cc 85.8 (134)
2 countries Turkey Slaughter/retail 2014 Cj 66.2 (74) [6]
Poland Bydgoszcz Poultry Slaughter/retail 2011 Cj 62.2 (90) [63]
2013 Cc 74.1 (54)
UK Multiple Chicken Retail 2014 Cj 49.1* (230) [16]
2015 Cc 54.7* (53)
Ruminants Africa Ghana Cattle Faeces/carcasses 2013–14 C. spp. 42.6 (54) [60]
Sheep Faeces/carcasses 2013–14 C. spp. 32.8 (64) [60]
Goat Faeces/carcasses 2013–14 C. spp. 47.4 (57) [60]
USA Michigan Cattle Faeces 2012 Cj 16.3 (22) [40]
USA 5 States Cattle Faeces 2012–13 Cj 35.4 (320) [33]
Cc 74.4 (115)
Swine China Multiple Pig Faeces 2008–14 Cc 97.0 (970) [39]
Africa Ghana Pig Faeces/carcasses 2013–14 C. spp. 30.3 (66) [55]
Europe 7 countries Pig Caecae 2015 Cc 62.1 (704) [13]
*Cj (C. jejuni); Cc (C. coli); C. spp. (Unspecified species of the genus Campylobacter).
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In members of the genus Campylobacter, FQ-resistance is
encoded on the chromosome and may therefore be expected
to be less transmissible between lineages than AMR that are
encoded on highly mobile plasmids. However, in highly
recombining bacteria such as C. jejuni and C. coli, there is
frequent natural transformation [5, 14] that may facilitate
the spread of resistance genes. It is difficult to separate the
role of mutation and HGT in conferring quinolone resistant
phenotypes from DNA sequence data alone, but the distri-
bution of resistance among relatively distant lineages (clonal
complexes, CC’s) is consistent with widespread acquisition
by mutation and recombination. The most likely evolution-
ary scenario is that CIP-resistance originates from indepen-
dent point mutations in the gyrA gene or horizontal
acquisition of resistance-encoding sequence(s). Mutants
may proliferate locally but since the gyrA mutation does not
incur a strong fitness cost on the recipient genotype, it per-
sists in the absence of selective pressure [14]. When com-
pared with C. jejuni, C. coli tends to have a greater
proportion of isolates that are resistant to CIP, along with
other AM’s [4, 6, 7, 15, 16]. There are several potential rea-
sons for the higher FQ resistance in C. coli. First, specific
mutations or natural transformations may occur at higher
frequencies. For example, strains belonging to the C. coli
828 clonal complex show evidence of extremely high levels
of interspecies recombination, with around 10% of the
genome introgressed from C. jejuni [47, 48]. Second, it is
also possible that uncharacterized genes or adaptations may
be present in C. coli, such as those associated with gentami-
cin resistance [49]. Third, the majority of C. coli isolated
from clinical and agricultural sources belong to a single
clonal complex (the ST-828 complex). Resistance mecha-
nisms associated with this expansion will be shared by a
large proportion of isolated strains. A more detailed under-
standing of the development and maintenance of AMR in
strains and species of the genus Campylobacter will depen-
dent upon analysis of exposure, transmission, strain muta-
tion/recombination frequency and the fitness cost of
adaptations to different AMs in the absence of selective
pressure [7].
Predicting resistance from whole-genome data
Advances in whole-genome sequencing (WGS) technology
and analysis have greatly improved understanding of the
genetic basis of phenotypic variation. Large numbers of
genomes of members of the genus Campylobacter are now
routinely sequenced, and this has considerable potential for
improving understanding of the evolution of FQ resistance
[5]. A recent study correlated multiple in vitro antimicrobial
resistance phenotypes with WGS genotype data [50]. Pre-
dictions based upon genomic variation were >99% accurate,
indicating that WGS may be a powerful tool for AMR sur-
veillance programs. Other sequence-based approaches have
also accurately detected the single point mutation in the
gyrA gene in phenotypically confirmed CIP-resistant mem-
bers of the genus Campylobacter [24] and the European
Committee for Antimicrobial Susceptibility Testing
(EUCAST) is currently reviewing the use and accuracy of
WGS as a predictor of AMR [51] for surveillance and moni-
toring programs.
To demonstrate the utility of studying putative CIP resis-
tance using genome data, we analysed assembled draft
genomes archived on the Sheppardlab BIGSdb [52]
(Table S1, available in the online version of this article).
Briefly, gyrA allelic variants were identified among isolate
genomes from human (clinical), chicken (faeces and meat)
and ruminant (cattle and sheep faeces and meat) samples.
Gene homology was defined using BLAST, with those found
to have >70%nucleotide identity in >50% of the continu-
ous sequence length, considered to be homologous. While
the number of homologues identified would vary depending
on the identity threshold, we used these as they are the
default settings within the database [52]. Putative resistance
genes and the proportion containing threonine and isoleu-
cine at amino acid position 86 were compared after align-
ment using the MEGA program, version 7.0. This allowed
comparison of putative CIP resistance in the genomes of
1844 isolates of members of the genus Campylobacter
(Fig. 1). This demonstrates the utility of WGS for making
predictions about resistance phenotypes on the basis of
sequence variation in genes for which the putative function
is known. There is some evidence for increasing resistance
over time among strains from humans, chickens and rumi-
nants but this is not a structured study so further analysis
would be needed.
Ciprofloxacin resistance among clinical isolates
Estimates of the proportion of CIP-resistant isolates of
members of the genus Campylobacter from clinical samples
vary considerably between published studies [6, 15, 17, 25,
39, 53–57] (Table 1). An increasing trend in the proportion
of clinical CIP-resistant isolates of members of the genus
Campylobacter has been reported in 2015 for 5 out of 17
(for C. jejuni) and 2 out of 13 (for C. coli) European member
states [15]. In England, Scotland and Wales, CIP-resistant
members of the genus Campylobacter increased from 7% of
clinical isolates in 1995 to 38% in 2008, with a similar trend
observed among C. jejuni in Northern Ireland (from 9% in
1996 to 32% in 2007) [58, 59]. While direct contextualiza-
tion with isolates from the USA is not possible because of
differences in data collection, the proportion of CIP-resis-
tant clinical isolates was seen to increase from 22%
(2004–2010) to 25% (2011–2012) [55] with a similar level
of resistance observed in C. jejuni from human infections
reported in Canada (2002–2014) [17].
Reports of reductions in the proportion of CIP-resistant
members of the genus Campylobacter from human infec-
tions are comparatively rare. None of the EU countries with
AMR data covering the previous three years (2013–2015)
reported declining trends of CIP resistance in isolates of
members of the genus Campylobacter from humans [15].
Furthermore, the members of the EU and the USA are
thought to be among the countries with a lower resistance
burden, and global trends indicate a higher proportion of
CIP resistance in other countries. For example, among
Sproston et al., Microbial Genomics 2018;4
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clinical samples from China a sustained increase has led to a
rise of CIP resistance in C. jejuni from 78% (1994–2002) to
90% (2003–2010) [25]. Consistent with this, foreign travel
is a major risk factor for infection with FQ-resistant Cam-
pylobacter. Studies in Canada, the USA and the UK revealed
that individuals that had travelled abroad were more likely
to have CIP-resistant strains [17, 39, 55]. In the USA 62.4%
of infections with members of the genus Campylobacterac-
quired abroad were CIP-resistant compared with 14.4% of
domestically acquired infections and CIP-resistant strains
were five times more likely to have been acquired abroad
than domestically in the UK [39, 55].
Ciprofloxacin resistance in livestock
Consistent with the high levels of FQ resistance in clinical
samples, numerous studies have reported CIP-resistant
members of the genus Campylobacter in livestock, including
ruminants [33, 40, 60], swine [15, 46, 60], poultry [6, 24, 46,
61, 62] and poultry retail meat [6, 16, 63, 64] (Table 1). In
cattle from the USA, 16% of C. jejuni isolated from gut and
faecal samples (2014) were resistant to CIP [40] and in iso-
lates from faeces and carcasses of cattle from Africa (2013–
2014), the proportion of CIP-resistant species of the genus
Campylobacter was 43% [60]. Resistance was even more
common among C. coli from fattening pigs in Europe
(2015) with 62% of isolates displaying CIP resistance [15].
As in clinical samples over a similar period, there is also evi-
dence for an increasing trend in CIP-resistant members of
the genus Campylobacter from beef and dairy cattle in the
USA (2013–2014) [4] and broiler chickens from various
European countries (2008–2014) [6]. In Austria and Spain
the proportion of CIP-resistant C. jejuni from broilers
remained stable over this period, as did resistance in C. coli
isolated in France, although they remained at a relatively
high prevalence. The only European country in which a
reduction in the number of CIP-resistant C. jejuni and
C. coli isolated from broilers was observed over this period
(2008–2014) was the Netherlands [6].
Potential for spread of resistance from animals to
humans
The transmission of FQ-resistant bacteria from agricultural
animals to humans is difficult to prove and a recent global
report on surveillance of antimicrobial resistance emphas-
ised the need to collect more data on the effects of AMR in
foodborne bacteria on animal and human health [21, 65].
Currently, there is little direct evidence of the transmission
of FQ-resistant bacteria within livestock and to humans via
food. The occurrence of resistant members of the genus
Campylobacter on retail poultry meat is a major concern
since this is a principal source of isolates infecting humans
[3, 66]. Data covering the last three years reveals an overall
increase in CIP-resistance among both C. jejuni and C. coli
Fig. 1. Proportion of genomes of isolates of members of the genus Campylobacter containing putative ciprofloxacin resistance. Isolate
genomes that contained a complete gyrA gene sequence from 1038 human (Blue), 670 chicken (Orange) and 136 ruminant (Grey) sam-
ples collected from 1978 to 2017 were compared. (a) The percentage of isolates containing isoleucine at amino acid position 86 was
determined and (b) the total number of samples was recorded.
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isolates from chicken meat [6]. In the USA, CIP-resistance
among isolates from chicken breast meat increased from 15
to 17% (C. jejuni) and from 10 to 26% (C. coli) from 2002
to 2007 [67], and a separate study recorded a similar rise
among C. jejuni isolates between 2013 and 2014 [4]. In UK
studies, the proportion of CIP-resistant C. jejuni and C. coli
isolated from retail chicken showed a similar increase
between 2007–2008 and 2014–2015 with the proportion of
resistant C. jejuni and C. coli isolates increasing from 21 to
49% and from 35 to 53%, respectively [16, 68]. Interest-
ingly, samples from frozen chicken were more likely to con-
tain ciprofloxacin-resistant isolates [68]
It has been noted that the proportion of CIP-resistant mem-
bers of the genus Campylobacter in poultry meat is often
strikingly similar to the proportion observed in human clin-
ical cases [6, 16, 58, 69]. In China, broilers and chicken
meat showed the highest Campylobacter CIP resistance at
99 to 100%, which corresponds to the extremely high levels
recorded in human isolates at 90% between 2003 and 2010
[25, 61, 64]. Likewise, in Poland 66% of human clinical iso-
lates of members of the genus Campylobacter were CIP-
resistant, which was similar to the 67% sampled from
chicken meat (Table 1) [63]. In the case where the direct
consumption of FQ-resistant bacteria leads to human infec-
tion, it is compelling to conclude that the use of antimicro-
bials to treat animals potentially erodes the efficacy of
important human drug treatments. The antimicrobial resis-
tance in C. jejuni and C. coli of both animal and human ori-
gin, has a strong correlation with the amount of
antimicrobial use in the animal production system (mg per
kg of meat produced). Those with stricter guidelines tend to
have lower proportions of resistant isolates (e.g. Nordic
countries) [7, 70]. However, using WGS to identify the gyrA
mutations in isolates of members of the genus Campylobac-
ter from poultry failed to cluster isolates according to the
country of origin or the current use of FQ in livestock pro-
duction [45]. In addition, data from the USA Centre for
Disease Control National Antimicrobial Resistance Moni-
toring System database [54] indicates that the 2005 USA
ban on the use of FQ’s in livestock has had little effect on
the increasing FQ-resistance among C. jejuni isolates from
clinical samples.
The fate of genomic variation associated with resistance is at
least partially determined by fitness. Substitutions that
impose little or no fitness cost on the cell have a higher
probability of persisting in the absence of antibiotic treat-
ment [71]. It is known that FQs impose a fitness cost in
members of the genus Campylobacter but this can vary
depending on strain and study conditions, with resistance
potentially persisting for some time in the absence of FQs
[72], potentially associated with compensatory mutations
that alleviate the costs of resistance. This means that live-
stock may not just act as transient vehicles of FQ resistance
but are dissemination points where members of the genus
Campylobacter resistant to FQ’s can persist and circulate
within the animal population for several years following the
decreased use of AM’s [7]. However, production systems
that use AMs at a higher rate present an increased risk of
resistant isolates spreading, at least on a local scale. Moni-
toring of AMR is seriously lacking in many countries [21]
where this, along with different practices and regulations, is
associated with wide variation in AMR between different
countries [7]. Because of trade networks, global implemen-
tation of monitoring and restriction of the use of AM’s in
livestock would be beneficial in the fight against AMR, with
more detailed information on AM usage at local, regional
and national scales to more accurately assess the potential
risk of transfer to humans [7, 21, 70].
Conclusions
The mechanisms by which FQ-resistance is acquired in
Campylobacter (mutation and HGT) are well established,
and routine surveillance of resistance phenotypes in clinical
samples describe a continued and sustained increase in
many countries. This trend is mirrored in isolates from live-
stock, especially chickens, which are a major source of
human disease. It is difficult to quantify the extent to which
the use of antimicrobials in agriculture reduces the efficacy
of drugs such as fluoroquinolones in treating human infec-
tions. This is exacerbated by the slow rate at which FQ-
resistance in Campylobacter is purged in the absence of
AMs, meaning that, once acquired, resistance can be main-
tained in populations despite restrictions on the use of FQ’s
in animal production. WGS offers a potential tool for
improving understanding of the emergence and mainte-
nance of AMR among members of the genus Campylobacter
from multiple host species. On the basis of AMR phenotype
predictions from large population genomic datasets it will
be possible to more accurately characterize source and sink
populations, environmental reservoirs and specific micro-
evolutionary events associated with acquisition, mainte-
nance and spread of resistance.
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